TY - JOUR T1 - Pregnancy pharmacoepidemiology: How often are key methodological elements reported in publications? JF - medRxiv DO - 10.1101/2021.05.04.21256602 SP - 2021.05.04.21256602 AU - Andrea V Margulis AU - Alison T Kawai AU - Mary S Anthony AU - Elena Rivero-Ferrer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/06/2021.05.04.21256602.abstract N2 - Purpose Publications are an important information source for clinicians, researchers, and patients. Key methodological elements must be reported for maximum transparency. We identified key methodological elements necessary for fully understanding pharmacoepidemiological research in pregnancy and quantified the proportion of studies that report these elements in a sample of publications.Methods Key methodological elements were identified from guidelines from regulatory agencies, literature, and subject-matter knowledge: source of information to determine pregnancy start; mother- or father-infant linkages (process, success rate); unit of analysis; and whether non-live births and fetuses with various anomalies were included in the study population.We conducted a literature review for recent observational studies on medical product utilization or safety during pregnancy and estimated the prevalence of reporting these elements.Results Data were extracted from a random sample of 100 publications; 8% were published in epidemiology/pharmacoepidemiology journals; 85% were medical product–safety studies.Of included publications, 43% reported the source for determining pregnancy start; 57% reported whether the study population included multifetal pregnancies; 39%, whether it included more than 1 pregnancy per woman; 27%, whether it included fetuses with chromosomal abnormalities; 60%, fetuses with major congenital malformations; and 93%, non-live births. Of the 20 studies with mother-infant linkage, 35% described the process; 21% reported the linkage success rate. Among studies with more than one pregnancy/offspring per woman, 22% reported methods addressing sibling correlation.Conclusions In this sample of pregnancy-related pharmacoepidemiology publications, completeness of reporting can be improved. A pregnancy-specific checklist would help to increase transparency in the dissemination of study results.Key points▪ Publications on the utilization or safety of medical products in pregnancy (pregnancy pharmacoepidemiology) are fully understandable when all key methodological elements are presented to the reader.▪ We identified 17 methodological elements from guidelines, literature, and subject-matter knowledge that we felt were crucial for understanding publications on pregnancy pharmacoepidemiology.▪ In a random sample of 100 publications, completeness of reporting varied across elements, with almost perfect reporting on whether non-live births were included in the study population to a 21% completeness on mother-infant linkage success rate.▪ A pregnancy-specific checklist would help to increase transparency in the dissemination of study results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll authors are employees of RTI Health Solutions, a unit of RTI International, which is an independent, not-for-profit organization that conducts work for government, public, and private organizations including pharmaceutical companies. The authors do not have any conflicts of interest for this work. Development of this manuscript was supported financially by RTI Health Solutions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a literature review; no IRB or other ethics review is needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are contained within the manuscript and its appendices. ER -